Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 4 |
| List of Tables | 8 | 1 |
| List of Figures | 8 | 2 |
| Pharmaceutical Supply Chain in the US - Introduction | 10 | 1 |
| Pharmaceutical Supply Chain in the US - Introductory Issues | 11 | 10 |
| Evolution of Supply Chain Management | 11 | 2 |
| The Pharmaceutical Supply Chain - Operational Issues | 13 | 1 |
| Demand Management with Adequate Forecast Tools to Reduce Inventory Levels | 13 | 1 |
| Optimum Inventory Levels Help to Maintain Flow of Working Capital | 13 | 1 |
| Supply Chain Performance Visibility in Pharmaceutical Supply Chain Management | 13 | 1 |
| Key Uncertainties in Production Planning and Scheduling | 14 | 1 |
| Forecasting Managers have to Deal with the Uncertainty in Demand for Existing Drugs | 14 | 1 |
| Uncertainties Experienced by Pipeline Drugs | 15 | 1 |
| Different Supply Chains in Pharmaceutical Industry | 15 | 1 |
| Reverse Logistics Evolving as a Significant Part of the Pharmaceutical Supply Chain | 15 | 1 |
| High Costs Due to Drug Callbacks | 16 | 1 |
| Recall Management could Prove Effective if Visibility in the Supply Chain Increases | 17 | 1 |
| Risk Management in Pharmaceutical Supply Chain Management | 18 | 2 |
| Radio Frequency Identification Technology to Play an Important Role in Improving Performance Visibility of the Pharmaceutical Supply Chain | 20 | 1 |
| Pharmaceutical Supply Chain in the US - Supply Chain Models | 21 | 6 |
| Pharmaceutical Supply Chain Models | 21 | 1 |
| Traditional Wholesaler Model | 21 | 1 |
| Advantages: faster and more frequent service | 21 | 1 |
| Disadvantages: easy target for counterfeits | 21 | 1 |
| Limited Distribution Model or Specialty Pharmacy Distribution Model | 22 | 1 |
| Advantages: cost reduction and better inventory management | 22 | 1 |
| Disadvantages: deterioration of patient-pharmacist relationship | 22 | 1 |
| Direct Distribution Model | 23 | 1 |
| Advantages: clearer supply chain visibility and control over counterfeit intrusion | 24 | 1 |
| Disadvantages: frequency of delivery affected and increased workload on pharmacists | 24 | 1 |
| Steps to Rationalize Existing Supply Chain | 24 | 1 |
| Cold-chain Storages to Play Critical Role in Supply Chain Management | 25 | 1 |
| Case Study - Implementing Lean Six Sigma to Revamp Pharmaceutical Company Performance | 26 | 1 |
| Pharmaceutical Supply Chain in the US - Securing a Supply Chain | 27 | 21 |
| Food and Drug Administration s Role in Addressing Counterfeiting Issues | 27 | 1 |
| Case Study: How Counterfeits were Identified at the Border | 27 | 1 |
| Case Study: Wholesale Distributor Involved in Diversion Schemes | 28 | 1 |
| Case Study: Pharmacies and Pharmacist Involved in Drug Diversion of Samples | 29 | 2 |
| Counterfeiting | 31 | 1 |
| Case Study: Fake Cases of Cancer Drug Avastin Raises Issues of Secured Supply Chain Management | 31 | 1 |
| New Technologies Affecting the Performance of the Supply Chain | 32 | 1 |
| E-pedigree Track-and-trace Systems | 32 | 2 |
| California E-pedigree Implementation Model | 34 | 1 |
| Automation of Reports and Consolidated Orders System Reporting | 34 | 1 |
| Unique Device Identification for Improving the Traceability of Medical Devices | 34 | 1 |
| Radio Frequency Identification, Electronic Product Codes and Physical Mark up Language a Tested Anti-counterfeit Technology | 35 | 1 |
| Anti-counterfeiting Technology Classification | 35 | 1 |
| Overt Technology | 36 | 1 |
| Holograms/Diffractive Optical Elements | 36 | 1 |
| Optical Variable Device | 36 | 1 |
| Sequential Product Numbering | 36 | 1 |
| Security Graphics | 36 | 1 |
| Product Marking | 36 | 1 |
| Color-shifting Security Inks and Films | 36 | 1 |
| Film Wrappers | 37 | 1 |
| Shrink Seals and Bands | 37 | 1 |
| Breakable Caps | 37 | 1 |
| Sealed Tubes | 37 | 1 |
| Covert Technologies | 37 | 1 |
| Invisible Printing and Watermarks | 37 | 1 |
| Hidden Marks and Printing | 37 | 1 |
| Forensic Markers | 38 | 1 |
| Chemical Taggants | 38 | 1 |
| DNA Fragments | 38 | 1 |
| Micro-particle Taggants (Nanotaggants) | 38 | 1 |
| Isotope Ratio | 38 | 1 |
| Mass Serialization/Track-and-trace Technologies | 39 | 1 |
| The different types of technologies used under track and trace are: | 39 | 1 |
| Anti-counterfeiting Technologies and their Impact on Pharmaceutical Companies | 40 | 1 |
| Case Study: Sproxil to Benefit from Mobile Technology | 41 | 1 |
| Top Anti-counterfeiting Companies and their Innovative Technologies | 41 | 1 |
| Reed-Lane, Inc | 41 | 1 |
| Cortegra Group Inc | 42 | 1 |
| Nanolnk Inc | 43 | 1 |
| TraceLink Inc | 44 | 1 |
| Axway | 45 | 1 |
| Innovatum Inc | 46 | 1 |
| Vetter Pharma International GmbH | 47 | 1 |
| Pharmaceutical Supply Chain in the US - Legislative Specifications of Pharmaceutical Traceability Enhancement Code Act | 48 | 1 |
| Title l: Immediate Provisions to Enhance Patient Safety | 48 | 1 |
| Title ll: Development of RxTEC System | 48 | 1 |
| Title lll: Enhanced FDA and State Authorities | 48 | 1 |
| Title lV: RxTEC System Assessment | 48 | 1 |
| Title V: Uniform National Policy | 48 | 1 |
| Pharmaceutical Supply Chain in the US - Wholesale Sector | 49 | 5 |
| Market Leaders in the Wholesale Sector | 49 | 1 |
| Trends Seen Across the US Wholesale Industry | 49 | 1 |
| Prescription Drug Marketing Act of 1987 | 50 | 1 |
| Market Share of Wholesalers | 50 | 1 |
| McKesson | 51 | 1 |
| Company Profile | 51 | 1 |
| AmerisourceBergen | 52 | 1 |
| Company Profile | 52 | 1 |
| Cardinal Health Inc | 53 | 1 |
| Company Profile | 53 | 1 |
| Pharmaceutical Supply Chain in the US - Pharmacy Sector | 54 | 2 |
| The US Pharmacy Sector | 54 | 1 |
| Market Share of Different Channels in the US Pharmaceutical Supply Chain | 54 | 1 |
| Market Share of Top Three Chain Drug Stores in the US | 55 | 1 |
| Pharmaceutical Supply Chain in the US - Appendix | 56 | 5 |
| Market Definitions | 56 | 1 |
| Abbreviations | 56 | 1 |
| Bibliography | 57 | 1 |
| Research Methodology | 58 | 2 |
| Coverage | 58 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |
